Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
X4 Pharmaceuticals Inc
XFOR | US
4.04
USD-0.07
-1.70%
XFOR | US
Loading StockChartView...
About X4 Pharmaceuticals Inc
Sector
Healthcare
Industry
Biotechnology
Earnings date
30/06/2024
As of date
02/06/2026
Close
4.04
Open
4.25
High
4.25
Low
4.01
X4 Pharmaceuticals Inc. a late-stage clinical biopharmaceutical company focuses on the research development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4) which is in Phase III clinical trial for the treatment of patients with warts hypogammaglobulinemia infections and myelokathexis syndrome; and Phase Ib clinical trial to treat chronic neutropenia and Waldenström macroglobulinemia. The company is also developing X4P-002 a CXCR4 antagonist for the treatment of brain cancers; and X4P-003 a CXCR4 antagonist for the treatment of CXCR4 disorders and primary immunodeficiencies. It has a license agreement with Abbisko Therapeutics Co. Ltd. to develop manufacture and commercialize mavorixafor in combination with checkpoint inhibitors or other agents in oncology indications. The company is headquartered in Boston Massachusetts.
View LessXFOR | US
Risk
55.6
Sharpe
0.11
Luna's Score
42/100
Recommendation
Sell
Luna says (XFOR | US)
What's Working
Low Market Beta (-0.4 to 0.8)
Value Stock (Price to Book < 3)
What's not Working
Weakness based on declining price with high volume
High 6-Month Volatility (>65%)
Smallcap (300M - 2B USD)
High Debt to Equity (> 0.75)
Weak Operating Margin (< 10%)
Weak Sharpe Ratio (< 0.3)
Volatility Signals
Bearish: Increased Volatility (6-month > 1-month volatility)
Risk Meter
Loading RiskMeterView...
10 days
54.4%1 month
55.6%3 months
81.6%6 months
77.1%Returns
Loading ReturnMeterView...
Fundamental Ratios
PE
4.00
Fwd. PE
-
Price to book
0.93
Debt to equity
0.83
Debt to assets
0.37
Ent. to EBITDA
1.10
Ent. to rev.
50.27
PEG
-
Other Fundamentals
EBITDA
-123.18M
MarketCap
680.74M
MarketCap(USD)
680.74M
Div. yield
-
Op. margin
-6.02K
Erngs. growth
-
Rev. growth
-
Ret. on equity
21.77
Short ratio
18.82
Short perc.
8.12
Market Sentiment (SMA and Price signals)
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
SMAs: Stock Price Trends
Loading MovingAverageView...
Range10D
0.80
Range1M
1.04
Range3M
1.58
Volumes: Market Activity
Volume Averages
Loading VolumeAverageView...
Rel. volume
1.23
Price X volume
1.86M
Peers
Diversifiers
Industry Comparison
| Parameter | Company | Industry | Indicator |
|---|---|---|---|
| Enterprise to EBITDA | 1.10 | 0.53 | Expensive |
| Ent. to Revenue | 50.27 | 3,967.00 | Cheaper |
| PE Ratio | 4.00 | 41.03 | Cheaper |
| Price to Book | 0.93 | 15.55 | Cheaper |
| Dividend Yield | - | 2.20 | - |
| Std. Deviation (3M) | 81.59 | 72.80 | Par |
| Debt to Equity | 0.83 | -1.23 | Expensive |
| Debt to Assets | 0.37 | 0.25 | Expensive |
| Market Cap | 680.74M | 3.66B | Emerging |
